567 related articles for article (PubMed ID: 29855323)
21. Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.
Sui H; Ma N; Wang Y; Li H; Liu X; Su Y; Yang J
J Immunol Res; 2018; 2018():6984948. PubMed ID: 30159341
[TBL] [Abstract][Full Text] [Related]
22. Abscopal regression following SABR for non-small-cell-lung cancer: A case report.
Cong Y; Shen G; Wu S; Hao R
Cancer Biol Ther; 2017 Jan; 18(1):1-3. PubMed ID: 27922336
[TBL] [Abstract][Full Text] [Related]
23. Nivolumab instills hope in a hopeless situation in advanced nonsmall cell lung cancer with poor performance status.
Chandrakanth MV; Noronha V; Joshi A; Patil V; Mahajan A; Prabhash K
Indian J Cancer; 2017; 54(1):55-56. PubMed ID: 29199664
[No Abstract] [Full Text] [Related]
24. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
Rossi E; Sgambato A; De Chiara G; Casaluce F; Losanno T; Sacco PC; Santabarbara G; Gridelli C
Expert Rev Clin Pharmacol; 2016; 9(3):419-28. PubMed ID: 26681547
[TBL] [Abstract][Full Text] [Related]
25. Advances in Immuno-Oncology: Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer-Introduction.
Socinski MA
Semin Oncol; 2015 Oct; 42 Suppl 2():S1-2. PubMed ID: 26477469
[No Abstract] [Full Text] [Related]
26. Stereotactic radiotherapy in targeted therapy treated oligo-metastatic oncogene-addicted (non-small-cell) lung cancer.
Giraud N; Abdiche S; Trouette R
Cancer Radiother; 2019 Jul; 23(4):346-354. PubMed ID: 31130373
[TBL] [Abstract][Full Text] [Related]
27. [Progress in Immunotherapy for Squamous Non-small Cell Lung Cancer].
Wang S; Li J
Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):682-686. PubMed ID: 27760599
[TBL] [Abstract][Full Text] [Related]
28. [Treatment of non-small cell lung cancer].
Hopstaken JS; de Ruiter JC; van Diessen JNA; Theelen WSME; Monkhorst K; Hartemink KJ
Ned Tijdschr Geneeskd; 2021 Feb; 165():. PubMed ID: 33651512
[TBL] [Abstract][Full Text] [Related]
29. Abscopal effect and resistance reversion in nivolumab-treated non-small-cell lung cancer undergoing palliative radiotherapy: a case report.
Fiorica F; Belluomini L; Giuliani J; Urbini B; Milella M; Frassoldati A; Pilotto S; Giorgi C
Immunotherapy; 2021 Aug; 13(12):971-976. PubMed ID: 34180714
[TBL] [Abstract][Full Text] [Related]
30. Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects.
Niibe Y; Nishimura T; Inoue T; Karasawa K; Shioyama Y; Jingu K; Shirato H
BMC Cancer; 2016 Aug; 16(1):659. PubMed ID: 27542716
[TBL] [Abstract][Full Text] [Related]
31. [Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].
Bílek O; Bohovicová L; Demlová R; Poprach A; Lakomý R; Zdražilová-Dubská L
Klin Onkol; 2016; 29 Suppl 4(Suppl 4):78-87. PubMed ID: 27846725
[TBL] [Abstract][Full Text] [Related]
32. Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer.
Yin L; Xue J; Li R; Zhou L; Deng L; Chen L; Zhang Y; Li Y; Zhang X; Xiu W; Tong R; Gong Y; Huang M; Xu Y; Zhu J; Yu M; Li M; Lan J; Wang J; Mo X; Wei Y; Niedermann G; Lu Y
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):212-224. PubMed ID: 32417411
[TBL] [Abstract][Full Text] [Related]
33. Abscopal Effect Following Immunotherapy and Combined Stereotactic Body Radiation Therapy in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma: A Report of Two Cases and Literature Review.
Choi JS; Sansoni ER; Lovin BD; Lindquist NR; Phan J; Mayo LL; Ferrarotto R; Su SY
Ann Otol Rhinol Laryngol; 2020 May; 129(5):517-522. PubMed ID: 31875405
[TBL] [Abstract][Full Text] [Related]
34. Updates on immunotherapy in non-small cell lung cancer.
Shimanovsky A; Dasanu CA
Expert Opin Biol Ther; 2014 Apr; 14(4):411-8. PubMed ID: 24512518
[TBL] [Abstract][Full Text] [Related]
35. Radiation and immunotherapy combinations in non-small cell lung cancer.
Azghadi S; Daly ME
Cancer Treat Res Commun; 2021; 26():100298. PubMed ID: 33387868
[TBL] [Abstract][Full Text] [Related]
36. Targeting PD-L1 for non-small-cell lung cancer.
Feld E; Horn L
Immunotherapy; 2016 Jun; 8(6):747-58. PubMed ID: 27197542
[TBL] [Abstract][Full Text] [Related]
37. Long-term Local Control and Overall Survival After Radiotherapy in Oligoprogressive Patients During Treatment With Checkpoint Inhibitors.
Damen PJJ; Suijkerbuijk KPM; VAN Lindert ASR; Eppinga WSC; El Sharouni SY; Verhoeff JJC
Anticancer Res; 2022 Oct; 42(10):4795-4804. PubMed ID: 36191990
[TBL] [Abstract][Full Text] [Related]
38. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors.
Langer CJ
Am J Clin Oncol; 2015 Aug; 38(4):422-30. PubMed ID: 24685885
[TBL] [Abstract][Full Text] [Related]
39. The abscopal effect: inducing immunogenicity in the treatment of brain metastases secondary to lung cancer and melanoma.
Tracz JA; Donnelly BM; Ngu S; Vojnic M; Wernicke AG; D'Amico RS
J Neurooncol; 2023 May; 163(1):1-14. PubMed ID: 37086369
[TBL] [Abstract][Full Text] [Related]
40. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
